公开(公告)号：US20250011461A1

公开(公告)日：2025-01-09

申请号：US18609414

申请日：2024-08-02

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

IPC: C07K16/30 ,  A61K31/436 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/85 ,  C12N15/86

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

公开(公告)号：US20240390492A1

公开(公告)日：2024-11-28

申请号：US18617912

申请日：2024-03-27

Applicant: Novartis AG

Inventor： Boris Engels ,  Carla Patricia Guimaraes

IPC: A61K39/00 ,  C07K14/705 ,  C12N5/0783

Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.

公开(公告)号：US11975026B2

公开(公告)日：2024-05-07

申请号：US17104961

申请日：2020-11-25

Applicant: Novartis AG

Inventor： Boris Engels ,  Carla Patricia Guimaraes

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783

CPC classification number: A61K35/17 ,  C07K14/70503 ,  C12N5/0636

Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.

公开(公告)号：US11578130B2

公开(公告)日：2023-02-14

申请号：US16210480

申请日：2018-12-05

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C07K14/74 ,  C12N9/12 ,  C12N9/90

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US20220364055A1

公开(公告)日：2022-11-17

申请号：US17271430

申请日：2019-08-30

Applicant: Novartis AG

Inventor： Louise Treanor ,  Michael R. Greene ,  Jennifer Brogdon ,  Boris Engels ,  Glenn Dranoff ,  Olja Kodrasi ,  Hyungwook Lim ,  Akash Sohoni ,  Elizabeth Dorothy Pratico ,  Anniesha Hack ,  Aida Abujoub ,  Tony Fleming ,  Lu Huang ,  Connie Hong ,  John Blankenship ,  Brian Holmberg ,  Chonghui Zhang ,  Dexiu Bu ,  Andrew Price ,  Xu Zhu ,  Andrew Stein ,  Attilio Bondanza

IPC: C12N5/0783 ,  A61K35/17 ,  A61K31/519 ,  A61K38/20 ,  C07K16/28 ,  C07K14/705

Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.

公开(公告)号：US20210220404A1

公开(公告)日：2021-07-22

申请号：US17104983

申请日：2020-11-25

Applicant: Michael R. Greene ,  Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Attilio Bondanza ,  Jennifer Brogdon ,  Dexiu Bu ,  Serena De Vita ,  Glenn Dranoff ,  Boris Engels ,  Tony Fleming ,  Brian Walter Granda ,  Michael R. Greene ,  Carla Patricia Guimaraes ,  Anniesha Hack ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Olja Kodrasi ,  Joni Waiee Lam ,  Hyungwook Lim ,  Elizabeth Dorothy Pratico ,  Andrew Price ,  Akash Sohoni ,  Andrew Marc Stein ,  Louise Treanor ,  Chonghui Zhang ,  Xu Zhu

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395 ,  C07K14/705 ,  A61K38/17 ,  C12N5/0783 ,  C07K14/725

Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

公开(公告)号：US10287354B2

公开(公告)日：2019-05-14

申请号：US15105074

申请日：2014-12-19

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C12N9/90 ,  C07K14/74

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US20190000944A1

公开(公告)日：2019-01-03

申请号：US16065387

申请日：2016-12-21

Applicant: Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe ,  Novartis AG ,  The Trustees of the University of Pennsylvania ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06

Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：US20170081411A1

公开(公告)日：2017-03-23

申请号：US15126037

申请日：2015-03-13

Applicant: Boris Engels ,  Andreas Loew ,  Michael C. Milone ,  Li Zhou ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Boris Engels ,  Andreas Loew ,  Michael C. Milone ,  Li Zhou

IPC: C07K16/28 ,  C12N15/62 ,  A61K38/17 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725

CPC classification number: C07K16/2863 ,  A61K38/00 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/0011 ,  A61K39/3955 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55561 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70575 ,  C07K16/00 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/22 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/10 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/70 ,  C07K2319/73 ,  C12N15/62

Abstract: Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.